Selva Nataraja

Selva received his PhD in biochemistry from the Indian Institute of Science, Bangalore, India. Following a postdoctoral stint at the Weizmann Institute of Science, Israel, he moved to University of Illinois at Chicago as a Research Associate. In 2000 he joined Serono/EMD Serono to start his drug discovery experience. He has supported programs in both small molecule and biotherapeutics and in multiple therapeutic areas, including Women’s health, Oncology and Immunology. In 2013, he spun out a project from EMD Serono to become an entrepreneur and formed Tocopherx to lead optimize of a small molecule. As founder & head of biology, he was instrumental in setting up the strategy for the company and drive the operations with external providers including CROs, academic and clinical investigators to successfully develop two clinical candidates. Selva joined Mitobridge in 2018 as project director and contributed significantly to late-stage programs and providing BD support for evaluating several external assets and technology platforms. As DDRL, he was instrumental in leading the BACH1 project for successful IND submission and supported nonclinical studies for programs in clinic. Selva brings in wealth of experience from a distinguished drug discovery career, in early and late preclinical development and across multiple therapeutic areas. He possesses strong leadership skills and passion to develop novel therapies for patients.